Cost‐effectiveness analysis of human papillomavirus vaccines for the prevention of cervical cancer in India

Abstract

AbstractBackgroundHuman papillomavirus (HPV) vaccines represent an important strategic opportunity to prevent cervical cancer in low‐middle income countries, such as India. The economic evaluation of HPV vaccines is crucial to inform public‐health decisions; however, the scarce economic evaluations from India have focused on the value for money of bivalent vaccines and took a healthcare perspective. The aim of this study is to conduct a cost‐effectiveness analysis of all available HPV vaccines in India.Material and methodsThe Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model was used to evaluate the cost‐effectiveness of HPV vaccination of 12‐year‐old girls in India, from both healthcare and societal perspectives. Cervical cancer cases, deaths averted and the incremental cost per Disability Adjusted Life Years (DALY) averted were reported as primary outcomes. Sensitivity analysis was undertaken to handle any uncertainty or variability in the results.ResultsCompared with no vaccination, the incremental cost per DALY averted was USD 362.78 for nonavalent vaccine, USD 393.16 for quadrivalent vaccine and USD 432.24 for bivalent vaccine from a healthcare perspective. From a societal perspective, the incremental cost per DALY averted was USD 334.28 for nonavalent vaccine, USD 364.67 for quadrivalent vaccine and USD 403.75 for bivalent vaccine. Assuming constant prices per dose for all vaccines, the nonavalent vaccine dominated both quadrivalent and bivalent vaccines, indicating that it is the more cost‐effective strategy.ConclusionVaccinating girls against HPV is a cost‐effective strategy to reduce the incidence of cervical cancer and mortality due to cervical cancer in India.